The FDA’s Office of Prescription Drug Promotion reviewed promotional material about the drug and said it misrepresented its efficacy. The material stated Breztri Aerosphere saw a “difference observed in time to all-cause mortality (over 52 weeks),” but the FDA said this is misleading since no COPD medications have proven a positive result on all-cause mortality.
This misbranding is in violation of the Federal Food, Drug, and Cosmetic Act and “makes its distribution violative,” the warning letter said. The letter is dated Aug. 4 and was posted to the agency’s website on Aug. 15.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
